Medtronic pins FY27 organic growth at about 5.5% to 6%, supported by Neuroscience acceleration and sustained MedSurg momentum, while CAS remains a strong contributor. MiniMed adds a modest uplift, and the company emphasizes that CAS will not slow, underpinning the diversified path to the target.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What drives the 5.5%-6% organic growth guidance for FY27 excluding the extra selling week, and which segments offset CAS to support that outlook?
Management framed FY27 organic growth (excluding the extra selling week) as underlying ~5.5% to 6%, an acceleration “in line with prior assumptions,” with the key market concern being CAS (Cardiac Ablation Solutions) slowing. 1
Although the question asks about “offsets” to CAS, management largely pushed back on the premise that CAS would slow materially enough to threaten growth:
Implication for the 5.5%-6% organic number: the guidance’s confidence rests on management believing CAS stays strong (high-teens market growth and faster Medtronic growth), while other portfolio parts accelerate to bring overall growth to the target range. 2
A major offset to any perceived pressure (and a source of confidence in hitting the mid-single-digit range) is that Neuroscience is guided to accelerate across its franchises:
Implication: Neuroscience acceleration is positioned as a key contributor to overall organic growth meeting the ~5.5%-6% underlying range. 34
Medtronic guided that MedSurg had a strong Q4 and will help next year, but with growth expected to normalize rather than stay at the unusually strong quarter level:
Implication: MedSurg contributes to the guidance, but management is tempering expectations—meaning other growth engines must carry enough incremental growth to still reach 5.5%-6% underlying. 3
MiniMed was explicitly quantified as a relatively small contributor (described as basis-point level uplift in the construct):
Implication: MiniMed provides incremental support, but it’s not the primary driver; the bulk of the confidence comes from accelerating franchises elsewhere (notably Neuroscience and continued strength in Cardiovascular/CAS dynamics). 3
The transcript segmenting around “offsets” points to Neuroscience acceleration and continued (but somewhat normalized) MedSurg momentum, with Cardiovascular/CAS itself not treated as a negative offset in management’s own framing.
| Segment / Franchise | Role in FY27 guidance (excluding extra week) | Supporting transcript detail |
|---|---|---|
| Neuroscience (all franchises accelerating) | Primary “offset”/balancing driver to ensure total growth reaches the 5.5%-6% underlying range even as markets worry about CAS | “Continuing in Neuroscience… Altaviva is off to a good start… [and] every single franchise in Neuroscience is going to accelerate.” 3 |
| Neuroscience sub-areas (esp. Neurovascular) | Reinforces acceleration through innovation + inorganic impact | Progress in Neurovascular expected to continue into FY27 with Neuroguard and MMA, plus inorganic impact coming from acquisitions. 4 |
| MedSurg (Surgical/CST/ACM/Endo referenced) | Provides continued momentum, but with normalization from Q4 strength | Surgical ~3% U.S./OUS; management expects MedSurg growth to normalize and not reflect fully the Q4 run-rate in FY27 guidance. 3 |
| MiniMed | Small positive uplift to the overall growth construct | Expected to “bring about sort of 20 to 25 basis points of growth” in FY27. 3 |
| CAS / Cardiovascular | Not treated as an offset; management expects CAS strength to persist | Management said CAS market will grow mid- to high-teens, Medtronic will grow north of 2x market rate, CAS annualizes at $2B and they do not expect CAS slowing to hurt growth. 2 |
All together, these elements are what management presents as the “puts and takes” underpinning confidence in the 5.5%-6% outcome. 134
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Medtronic reports robust Q1 2027 base business outside CAS, led by CRM, CST, and Surgical, with Altaviva offsetting SNM softness. The Cornerstone investment is a $700 million global initiative driving long-term growth, but near-term revenue timing is not disclosed, and management reduced the operating-margin expansion guidance by about 10 bps to fund reinvestments.
Sources used
Research questionPlease provide an update on Medtronic's base business excluding CAS, including Altaviva performance, plus details on the Cornerstone deal (timing of revenue impact in base Surgical, contract structure, geographic scope including whether the U.S. is included), and the margin guidance change (clarify the rationale behind lowering the operating profit margin expansion guidance by about 10 basis points)?
Answer outline
Medtronic reports a broad-based uplift in its base business excluding CAS for Q1 FY2027, led by CRM, CST, and Surgical strengths, with Altaviva beginning to contribute as reimbursement and training efforts scale. The Cornerstone investment is framed as a longer-term, globally focused platform that may deliver revenue gradually, while the company trims near-term operating-margin expansion by ~10 basis points to fund growth initiatives. Organic revenue guidance is raised despite the investment backdrop.
Sources used
Research questionPlease provide an update on Medtronic's base business excluding CAS, including Altaviva performance, plus details on the Cornerstone deal (timing of revenue impact in base Surgical, contract structure, geographic scope including whether the U.S. is included), and the margin guidance change (clarify the rationale behind lowering the operating profit margin expansion guidance by about 10 basis points)?
Answer outline
Medtronic reports that demand for valve procedures, particularly TAVR, has stabilized in the U.S. after a brief slowdown linked to low-risk data and market dynamics, guiding a steadier near-term outlook. The company is accelerating investment in DASI software within Structural Heart, supported by leadership changes and momentum, with a focus on mitral and tricuspid capabilities and an optimistic path forward.
Sources used
Research questionWhat did management say about Valve procedures demand and DASI software?
Answer outline
Medtronic's FY27 organic growth target of 5.5%-6% (excluding the extra selling week) rests on sustained CAS momentum and a diversified driver set across Neuroscience, Cardiovascular, and MiniMed/MedSurg contributions, supported by CRM innovations and Ardian growth.
Sources used
Research questionWhat drives the 5.5%-6% organic growth guidance for FY27 excluding the extra selling week, and which segments offset CAS to support that outlook?
Answer outline
Medtronic's Q4 2026 commentary indicates valve procedures demand has stabilized after a slowdown, with U.S. headwinds from low-risk data and large-size valve use. Management also underscores a strategic, accelerating investment in DASI software for mitral and tricuspid care, signaling execution momentum and an optimistic outlook.
Sources used
Research questionWhat did management say about Valve procedures demand and DASI software?
Answer outline
Medtronic asserts that Affera utilization is strongest at high-volume centers, with 75% of the U.S. installed base and ongoing expansion through additional systems and broader penetration into lower-volume sites. Management ties utilization to quarterly pull-through and notes the installed-base ramp is in early innings, supported by clinical evidence, reimbursement, and ecosystem initiatives to unlock a larger market opportunity.
Sources used
Research questionWhat did management say about Affera center utilization expansion?
Answer outline
Medtronic indicates Affera utilization expansion is in the early adopters stage, driven by high-volume centers with room to penetrate lower-volume accounts. Management notes strong pull-through within existing large accounts, rapid installed-base growth, and the perception of Affera as a workhorse technology, while acknowledging the lack of precise utilization metrics to quantify pace or ceiling.
Sources used
Research questionWhat did management say about Affera center utilization expansion?
Answer outline
Marvell attributes near-term data center margin pressure to the expanding mix of custom silicon, with management emphasizing that revenue levels and product mix drive gross margins each quarter. While the Q3 headwind is primarily a mix effect, management expects margins to stabilize as the custom ramp accelerates in H2 and broad-based growth supports margin expansion into fiscal 2028.
Sources used
Research questionWhat did management say about Data center margin drivers from custom mix?
Answer outline
Investors should read management’s “2H acceleration” as a qualitative uptick in the second half versus the first half, supported by guidance for sequential back-half growth and a Helios ramp that becomes more impactful in Q4. The Q2 107% YoY growth establishes the first-half baseline, with Q3 and Q4 expected to exceed it through supply and product timing.
Sources used
Research questionHow should investors interpret management’s view that data center AI growth will “accelerate” in the second half versus the first half, given Q2’s 107% year-over-year growth and the Q3/Q4 guidance trajectory?
Answer outline
Western Digital outlines a dual-path outlook: LTA pricing remains contract-driven and predictable, particularly for nearline pricing, while offering upside in non-nearline contracts, and the exabyte growth trajectory remains robust at 25% plus, supported by 40TB ePMR ramp and upcoming HAMR and higher-capacity drives, with visibility extending through 2029–2031. Quarterly margins may vary due to LTA timing, but the long-term demand signal remains strong.
Sources used
Research questionWhat did management say about LTA pricing and exabyte growth outlook?
Answer outline
Pfizer's update highlights a $1.5 billion year-to-date non-COVID uplift driven by Eliquis alongside other products like NURTEC and Padcev, though the exact split isn’t quantified. Eliquis is projected to grow 20%–25% this year, while Padcev shows an initial acceleration that should moderate as la/mUC penetration matures, with upside potential from MIBC over time.
Sources used
Research questionWithin the $1.5 billion year-to-date increase in non-COVID revenue guidance, how much is due to Eliquis versus other products, and what is the updated Eliquis growth outlook? Also, with Padcev's expanded label, what is the expected growth path for that asset going forward?
Answer outline
Match Group's Q2 2026 earnings discussion centers on a consistent MAU-payer trend correlation, where payer declines run smaller than MAU declines and payer penetration rose year over year. Management notes MAU momentum drives direct revenue per MAU and payer trends over time, but warns quarterly movements can diverge due to product and monetization initiatives, while maintaining a positive long-term outlook and guidance for payer declines to ease in H2.
Sources used
Research questionWhat did management say about MAU and payer trend correlation?
Answer outline
Dafinchi